2022 World Conference on Lung Cancer (ePosters)-EP08.01-093. ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer

EP08.01-093. ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer

Back to course

Pdf Summary

A study conducted at the Hunan Cancer Hospital in China evaluated the efficacy and safety of immune checkpoint inhibitors (ICI) in combination with chemotherapy or anti-angiogenic therapy as second-line or beyond treatment for advanced non-small cell lung cancer (NSCLC). The study aimed to expand the population responding to immunotherapy treatment.<br /><br />The study included a total of 145 previously treated NSCLC patients who received ICI monotherapy or combination therapy. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. The patients were divided into three groups: ICI monotherapy, ICI with chemotherapy, and ICI with anti-angiogenic therapy.<br /><br />The results showed that the combination therapy groups had significantly higher ORR, DCR, PFS, and OS compared to the ICI monotherapy group. The ICI/chemotherapy group had significantly higher ORR, DCR, and longer PFS and OS than the ICI monotherapy group. Similarly, the ICI/anti-angiogenic therapy group showed significantly higher DCR, and longer PFS and OS compared to the ICI monotherapy group. There was no significant difference between the ICI/chemotherapy group and the ICI/anti-angiogenic therapy group.<br /><br />The addition of chemotherapy or anti-angiogenic therapy to the ICIs did not increase immune-related adverse events and had a good safety profile.<br /><br />In conclusion, the study suggests that ICI/chemotherapy or ICI/anti-angiogenic therapy is well-tolerated and more effective than ICI monotherapy as a second-line or beyond treatment option for advanced NSCLC patients without prior immunotherapy. However, further verification of these findings is needed through prospective randomized controlled trials.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Hunan Cancer Hospital

China

immune checkpoint inhibitors

chemotherapy

anti-angiogenic therapy

non-small cell lung cancer

NSCLC

immunotherapy treatment

progression-free survival

objective response rate